George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11,988.00
Bid: 12,016.00
Ask: 12,020.00
Change: -38.00 (-0.32%)
Spread: 4.00 (0.033%)
Open: 12,070.00
High: 12,144.00
Low: 11,882.00
Prev. Close: 12,026.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Replacement Pfizer Inc

22 May 2014 12:53

RNS Number : 8347H
Morgan Stanley & Co. Int'l plc
22 May 2014
 



AMENDMENT

 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley & Co. International plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PFIZER INC

(c) Name of the party to the offer with which exempt principal trader is connected:

 

ASTRAZENECA PLC

(d) Date dealing undertaken:

09 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 COMMON STOCK

 PURCHASES

 991

 21.2450 EUR

 20.9400 EUR

 COMMON STOCK

 SALES

 200

 20.9550 EUR

 20.9300 EUR

 COMMON STOCK

 PURCHASES

 214,819

 29.0900 USD

 28.8150 USD

 COMMON STOCK

 SALES

 213,434

 29.0900 USD

 28.8421 USD

 

 

(b) Derivatives transactions (other than options)

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 

(ii) Exercising

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

22 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERATMBTMBATBMI
Date   Source Headline
30th Jul 20207:18 amRNSAZN: H1 2020 results
29th Jul 20207:00 amRNSBoard Committee Changes
28th Jul 20207:00 amRNSFarxiga DAPA-CKD trial met all endpoints
27th Jul 20207:10 amRNSCalquence receives positive CHMP opinion for CLL
27th Jul 20207:05 amRNSImfinzi recommended for EU approval in SCLC
27th Jul 20207:00 amRNSAstraZeneca enters collaboration in oncology
24th Jul 20207:00 amRNSBreztri Aerosphere approved in the US for COPD
22nd Jul 20203:00 pmRNSHolding(s) in Company
22nd Jul 20203:00 pmRNSHolding(s) in Company
21st Jul 20203:00 pmRNSHolding(s) in Company
21st Jul 20203:00 pmRNSHolding(s) in Company
20th Jul 20202:41 pmRNSCOVID-19 vaccine Phase I/II showed immune response
16th Jul 20207:00 amRNSDirector Declaration
9th Jul 20207:00 amRNSBrilinta granted US FDA Priority Review for stroke
8th Jul 20207:00 amRNSLynparza approved in the EU for pancreatic cancer
1st Jul 20203:00 pmRNSTotal Voting Rights
30th Jun 20203:00 pmRNSDirector/PDMR Shareholding
30th Jun 20207:00 amRNSSelumetinib granted Japan orphan drug designation
17th Jun 20203:03 pmRNSHolding(s) in Company
17th Jun 20203:00 pmRNSHolding(s) in Company
15th Jun 20207:00 amRNSAgreement to Supply Europe with COVID-19 Vaccine
11th Jun 20207:00 amRNSEMTN Programme Routine Technical Update
1st Jun 20203:00 pmRNSBlock listing Interim Review
1st Jun 20203:00 pmRNSTotal Voting Rights
1st Jun 20207:00 amRNSLynparza EU CHMP opinion in pancreatic cancer
1st Jun 20207:00 amRNSBrilinta obtains additional US approval
29th May 20204:41 pmRNSSecond Price Monitoring Extn
29th May 20204:35 pmRNSPrice Monitoring Extension
29th May 20201:00 pmRNSImfinzi sustained overall survival in CASPIAN
29th May 20201:00 pmRNSEnhertu DESTINY-Gastric01 results from ASCO 2020
29th May 20207:00 amRNSTagrisso unprecedented adjuvant lung cancer data
26th May 202010:30 amRNSDirector/PDMR Shareholding
22nd May 20207:00 amRNSEnhertu US orphan designation in gastric cancer
21st May 20207:00 amRNSAstraZeneca advances response to COVID-19 outbreak
20th May 20207:00 amRNSLynparza approved in the US for prostate cancer
18th May 20207:00 amRNSEnhertu US Breakthrough status for lung cancer
18th May 20207:00 amRNSBevespi Aerosphere approved in China for COPD
11th May 20207:00 amRNSBrazikumab rights recovered by AstraZeneca
11th May 20207:00 amRNSEnhertu designated gastric cancer BTD
11th May 20207:00 amRNSLynparza gets broader US ovarian cancer approval
6th May 20207:00 amRNSFarxiga approved by FDA for heart failure (HFrEF)
1st May 20203:00 pmRNSTotal Voting Rights
29th Apr 20204:00 pmRNSResult of AGM
29th Apr 20207:00 amRNSAZN: first-quarter 2020 results
24th Apr 20207:00 amRNSLynparza shows overall survival in prostate cancer
17th Apr 202011:00 amRNSChanges to arrangements for AGM
14th Apr 20207:00 amRNSTagrisso adjuvant trial overwhelmingly positive
14th Apr 20207:00 amRNSKoselugo (selumetinib) approved in the US for NF1
2nd Apr 20207:00 amRNSAstraZeneca divestment of Movantik completed
1st Apr 20203:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.